British pharmaceutical giant AstraZeneca said its COVID-19 vaccine candidate has produced a similar immune response among adults.
Raising hopes of a path out of the gloom and economic destruction brought by the novel coronavirus. The vaccine, developed by the University of Oxford, said adverse responses to the vaccine among the elderly were also found to be lower.
The World Health Organization has said that older people, in addition to people of all ages with preexisting medical conditions, appear to develop serious illness on contracting the coronavirus more often than others.
According to the AstraZeneca spokesman, “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher.”
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, referring to the technical name of the Oxford-AstraZeneca vaccine.
Previously, AstraZeneca CEO Pascal Soirot has said the drugmaker’s vaccine would likely provide protection against contracting the coronavirus for about a year.
Drugmakers and research centers are scrambling to deliver a safe and effective vaccine in an attempt to bring an end to the coronavirus pandemic.